PRETA, Laure-Helene; CONTEJEAN, Adrien; SALVO, Francesco; TRELUYER, Jean Marc; CHARLIER, Caroline; CHOUCHANA, Laurent

doi:10.1111/bcp.15280

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

PRETA, Laure-Helene

CONTEJEAN, Adrien

SALVO, Francesco

Bordeaux population health [BPH]

Langue

Article de revue

Ce document a été publié dans

British Journal of Clinical Pharmacology. 2022-07, vol. 88, n° 7, p. 3529-3534

Résumé en anglais

Several cases of herpes zoster (HZ) following mRNA COVID-19 vaccination (BNT162b2 and mRNA-1273) have been reported, and the first epidemiological evidence suggests an increased risk. We used the worldwide pharmacovigilance database VigiBase to describe HZ cases following mRNA COVID-19 vaccination. We performed disproportionality analyses (case/non-case statistical approach) to assess the relative risk of HZ reporting in mRNA COVID-19 vaccine recipients compared to influenza vaccine recipients and according to patient age. To 30 June 2021, of 716 928 reports with mRNA COVID-19 vaccines, we found 7728 HZ cases. When compared to influenza vaccines, mRNA COVID-19 vaccines were associated with a significantly higher reporting of HZ (reporting odds ratio 1.9, 95% CI 1.8–2.1). Furthermore, we found a reduced risk of reporting HZ among under 40-year-old persons compared to older persons (reporting odds ratio 0.39, 95% CI 0.36–0.41). Mild and infrequent HZ reactions may occur shortly after mRNA COVID-19 vaccination, at higher frequency than reported with influenza vaccination, especially in patients over 40 years old. Further analyses are needed to confirm this risk.< Réduire

Mots clés en anglais

COVID-19

Disproportionality

Herpes zoster

mRNA vaccines

Pharmacovigilance

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Association study between herpes zoster reporting and mRNA COVID‐19 vaccines (BNT162b2 and mRNA‐1273)

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche